Advertisement

Keywords

Parallel Trade Reference Price System Swiss Federal Statistics World Health Organization Regional European Commission Communication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. Addor, F (2004): “Parallelimporte patentierter Waren: Eine unendliche Geschichte?, Speaking notes, press seminar “Parallelimporte Patentgeschützter Medikamente”, Berne, June 29th, 2004Google Scholar
  2. Binder T. (2007): Pharmamarkt Schweiz 2006, IMS Health GmbH, Hergiswil http://www.ihaims.ch/Uploads/N274.pdfGoogle Scholar
  3. Bouvy. F (2003): Overview of pricing and reimbursement measures taken since January 1993, European Federation of Pharmaceutical Industry Associations (EFPIA), BrusselsGoogle Scholar
  4. Bouvy. F (2003): Reference Price Systems, an overview, Federation of Pharmaceutical Industry Associations (EFPIA), BrusselsGoogle Scholar
  5. Bundesamt für Gesundheit (2001): Die Obligatorische Krankenversicherung kurz erklärt, BerneGoogle Scholar
  6. Bundesministerium für Justiz: Sozialgesetzbuch-Fünftes Buch (V)-Gesetzliche Krankenversicherung (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGB1. I S. 2477), http://bundesrecht.juris.de/sgb_5/, accessed on 20.02.2006Google Scholar
  7. Cambridge Pharma Consulting (2002): Delays in Market Access, Cambridge, UKGoogle Scholar
  8. College Tarieven Gezondheidszorg: Tariefbeschikking, www.ctg-zaio.nl, accessed on 13.02.2006Google Scholar
  9. Danzon, P. (1997): Pharmaceutical Price Regulation, National Policies versus Global Interests, WashingtonGoogle Scholar
  10. Danzon, P. (2001): Reference Pricing Theory and Evidence, Wharton School, University of Pennsylvania, PhiladelphiaGoogle Scholar
  11. Department of Health (2006): 2005 Consultation Document Arrangements for the Provision of Dressings, Incontinence Appliances, Stoma Appliances, Chemical Reagents and Other Appliances to Primary and Secondary Care, LondonGoogle Scholar
  12. DiMasi. J, (2002): Price trends for prescription pharmaceuticals: 1995–1999, a background report for the department of health and human services, http://aspe.hhs.gov/health/reports/Drug-papers/dimassi/ dimasi-final.htm, accessed on 13.02.2006Google Scholar
  13. DiMasi, J. (2004): The economics of follow-on drug research and development, Pharmacoeconomics 2004; 22Suppl. 2: 1–14PubMedCrossRefGoogle Scholar
  14. DiMasi, J et al. (2003): The price of innovation: New estimates of drug developing costs, J. of Health Economics, 22 (2003) 151–185CrossRefGoogle Scholar
  15. Eidgenössisches Volkswirtschaftsdepartement (2000): Parallelimporte und Patentrecht. Bericht des Bundesrates vom 8. Mai 2002 in Beantwortung der Anfrage der Kommission für Wirtschaft und Aufgaben des Nationalrates (WAK) vom 24. Januar 2000Google Scholar
  16. European Commission (1982): European Commission Communication AB1 Nr. C 115, 06.05.1982Google Scholar
  17. European Court of Justice (1974): Judgement of the Court In Case 15/74, between Centrafarm BV et Adriaan de Peijper v Sterling Drug Inc.Google Scholar
  18. European Court of Justice (1998): Judgement of the Court In Case C-355/96, between Silhouette International Schmied GmbH & Co. KGGoogle Scholar
  19. European Court of Justice (1999): Judgement of the Court in Case C-173/98, between Sebago Inc. and Ancienne Maison Dubois et Fils SA and GB-Unic SAGoogle Scholar
  20. European Court of Justice (2001): Judgement of the Court in Case 15/01, between Paranova Läkemedel et al. vs. LäkemedelsverketGoogle Scholar
  21. European Court of Justice (2002): Opinion of Advocate General Léger in Case C-438/02, between Åklagaren v Krister HannerGoogle Scholar
  22. European Court of Justice (2004): Judgement of the Court in joined Cases C-2/01 P and C-3/01, between Bundesverband der Arzneimittel-Importeure eV et al. and Bayer AG et al.Google Scholar
  23. European Court of Justice (2006): Judgment of the Court of First Instance in Case T-168/01, between GlaxoSmithKline Services Unlimited and the Commission of European Communities et al.Google Scholar
  24. European Federation of Pharmaceutical Industries Association, EFPIA (2006): The Pharmaceutical Industry in Figures, 2006 Edition, BrusselsGoogle Scholar
  25. Frank R.G., Salkever D.S. (1997): Generic Entry and the Pricing of Pharmaceuticals, J. of Econ & Management Strategy, Spring, pp. 75–90Google Scholar
  26. Gansladt M, Maskus K (2001): Parallel Imports of Pharmaceuticals in the European Union, Working Paper No 546, 2001, The Research Institute of Industrial Economics, StockholmGoogle Scholar
  27. Ganslandt M., Maskus K.E. (2004): Parallel Imports of Pharmaceuticals in the European Union, J. of Health Economics 23 (2004) 1035–1057CrossRefGoogle Scholar
  28. Glenngård A. et al. (2005): Health Systems in Transition: Sweden, Vol. 7 No. 4, Page 48, European Observatory on Health Systems and Policies, CopenhagenGoogle Scholar
  29. Glynn D. et al. (1997): Survey of parallel trade, National Economic Research Associates NERA, LondonGoogle Scholar
  30. Haigh, J. (2003): Parallel Trade in Europe, Strategies for Global Corporations, IMS Health, LondonGoogle Scholar
  31. Huskamp, A et al. (2003): The Effect of Incentive-Based Formularies on Prescription-Drug Utilisation and Spending, N Engl. J Med 2003;349: 2224–2232.PubMedCrossRefGoogle Scholar
  32. Roth Johnsen J. (2006): Health Systems in Transition: Norway, Vol. 8 No. 1 2006, The European Observatory on Health Systems and Policies, Copenhagen, DenmarkGoogle Scholar
  33. IMS Consulting (2003): A comparison of pharmaceutical pricing in Switzerland with selected reference countries, LondonGoogle Scholar
  34. Infras/Basys (2002): Auswirkungen staatlicher Eingriffe auf das Preisniveau im Bereich Humanarzneimittel, Bericht im Auftrag des BundesratesGoogle Scholar
  35. International Trade Administration, U.S. Department of Commerce (2004): Pharmaceutical Price Controls in OECD Countries Implications for U.S. Consumers, Pricing, Research and Development, and Innovation, http://www.ita.doc.gov/td/health/DrugPricingStudy.pdfGoogle Scholar
  36. Interpharma (2006): Pharmamarkt Schweiz, Ausgabe 2005, BaselGoogle Scholar
  37. IMS Health (2006): Pricing and Market Access Review 2005, Cambridge, UKGoogle Scholar
  38. IPSE: Parallel-und Reimporte von Arzneimitteln, Rechtliche Rahmenbedingungen in der Bundesrepublik DeutschlandGoogle Scholar
  39. Kanavos P. and Costa-Font J (2005): Pharmaceutical parallel trade in Europe: stakeholder and competition effects, Economic Policy October 2005, p 778Google Scholar
  40. Knox, D, Richardson, M. (2002): Trade policy and parallel imports, European Journal of Political Economy Vol 19 (2002) 133–151, University of Otago, Dunedin, New ZealandGoogle Scholar
  41. Läkemedelindustrieföreningen, LIF (2006): FAKTA 2006, Pharmaceutical Market and Health Care, StockholmGoogle Scholar
  42. Legemiddelindustrieforenigen, LMI (2002): Facts and Figures 2006: Medicines and Healthcare, Oslo, Norway, http://www.lmi.no/FullStory.aspx?m=146Google Scholar
  43. Legemiddelindustrieforenigen, LMI (2006): Facts and Figures 2006: Medicines and Healthcare, Oslo, Norway, http://www.lmi.no/tf/2006/files/english/facts_and_figures_2006.pdfGoogle Scholar
  44. Legemiddelindustrieforenigen, LMI (2007): Facts and Figures 2007: Medicines and Healthcare, Oslo, Norway, http://www.lmi.no/tf/2007/english/facts_and_figures_2007.pdfGoogle Scholar
  45. Larsson. P (1999): Parallel Imports-Effects of the Silhouette Ruling, The Swedish Competition Authority, StockholmGoogle Scholar
  46. Maskus, K. E (2002): Vertical price control and parallel imports: theory and evidence, Washington D.C., The World Bank GroupGoogle Scholar
  47. Mepha Pharma AG (2005): Präsentation zur Jahres-Medienkonferenz, 03.02.2005Google Scholar
  48. Mepha Pharma AG (2007): Präsentation zur Jahres-Medienkonferenz der Mepha-Gruppe, 19.01.2007Google Scholar
  49. Morten Dalelen D. et al. (2006): Dag Morten Dalen et al. (2006), Price regulation and generic competition in the pharmaceutical market, University of Oslo, Health Economics Research Programme, Working Paper 2006.1Google Scholar
  50. El Mundo (2005): Sanidad rebaja el precio de unos 4.500 medicamentos, 01.03.2005, http://www.elmundo.es/elmundosalud/2005/03/0l/industria/l109675885.html, accessed 20.02.2006Google Scholar
  51. Nguyen, N (1997): Physician behavioural response to a Medicare price reduction, Health Service ResearchGoogle Scholar
  52. Pedersen K. et al. (2006): The economic impact of parallel import of pharmaceuticals, University of Southern Denmark, OdenseGoogle Scholar
  53. Poget, C. (2005): Are interventions in pharmaceutical markets an effective tool for cost containment? WWZ-Forschungsbericht, BaselGoogle Scholar
  54. Reiffen D. and Ward M. (2002): Generic Drug Industry Dynamics, The Federal Trade Commission, WashingtomGoogle Scholar
  55. Roth Johnsen J. (2006): Health Systems in Transition: Norway, Vol. 8 No. 1 2006, The European Observatory on Health Systems and Policies, Copenhagen, DenmarkGoogle Scholar
  56. Seydoux, Y (2005): Die schweizerische Bevölkerung bezahlt zu viel für Medikamente, Press Statement, Santésuisse, SolothurnGoogle Scholar
  57. Swiss Federal Statistics Office (2005): Kosten und Finanzierung des Gesundheitswesens 2003, NeuchâtelGoogle Scholar
  58. West P, Mahon. J (2002): Benefits to patients and payers from parallel trade, The York Health Economic ConsortiumGoogle Scholar
  59. Vallgårda S. et al. (2001): Healthcare Systems in Transition: Denmark, Vol. 8, Nr. 7, The World Health Organization Regional Office for Europe, CopenhagenGoogle Scholar
  60. Vaterlaus, S (2004): Auswirkungen eines Wechsels zur regionalen Erschöpfung im Patentrecht Aktualisierung und Ergänzung des Berichts «Erschöpfung von Eigentumsrechten: Auswirkungen eines Systemwechsels auf die schweizerische Volkswirtschaft», Plaut Economics, BerneGoogle Scholar
  61. Vaterlaus, S (2002): Erschöpfung von Eigentumsrechten: Auswirkungen eines Systemwechsels auf die schweizerische Volkswirtschaft, Plaut Economics, Berne, Frontier Economics, LondonGoogle Scholar
  62. Vaterlaus, S (2004): Warum erodieren Parallelimporte die Preisinsel Schweiz nicht stärker? Ermittlung der Rolle der geistigen Schutzrechte anhand exploratorischer Expertengespräche, Plaut Economies, BerneGoogle Scholar
  63. VFA (2004): Reimporte: Kostendämpfung auf dem Irrweg, http://vfa.de/de/politik/artikelpo/reimporte.html, acceeded on 15.02.2006Google Scholar
  64. Woodfield, A. (1999): Augmenting Reference Pricing of Pharmaceuticals with strategic cross-product agreements, University of Canterbury Working Paper, Christchurch, New ZealandGoogle Scholar
  65. World Health Organization, (2002): Healthcare Systems in Transition: Switzerland, The World Health Organization, CopenhagenGoogle Scholar
  66. World Trade Organisation: Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)Google Scholar

Copyright information

© Birkhäuser Verlag AG 2008

Personalised recommendations